OmniAb (OABI) Stock Price, News & Analysis

Company Overview

OmniAb, Inc. is a biotechnology company that develops and provides antibody discovery technologies for pharmaceutical and biotechnology companies. Its platform is designed to help partners identify fully human and humanized antibodies that can be developed into therapeutics for a range of diseases.

The company’s technologies include genetically engineered animals and related screening and selection systems, including its OmniRat, OmniMouse, OmniChicken and OmniFlic platforms. These tools are intended to generate diverse antibody candidates and support the discovery of antibodies with desired binding and functional characteristics.

OmniAb primarily serves biopharmaceutical partners through collaborations, licensing arrangements and other commercial relationships. The company was previously operated as part of Ligand Pharmaceuticals before becoming an independent, publicly traded company through a business combination with Avista Public Acquisition Corp. II in 2022. OmniAb is headquartered in Emeryville, California.

Key Stats

• Today's Range: $4.27 to $4.45
• 50-Day Range: $1.95 to $5.04
• 52-Week Range: $1.30 to $5.43
• Volume: 1.06 million shs
• Average Volume: 1.66 million shs
• Market Capitalization: $629.79 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $11.00
• Consensus Rating: Hold

OmniAb Stock Analysis - MarketRank™

OmniAb scored higher than 67% of companies evaluated by MarketBeat, and ranked 269th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Hold

Consensus Rating

OmniAb has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

OmniAb has a consensus price target of $11.00, representing about 152.9% upside from its current price of $4.35.

Amount of Analyst Coverage

OmniAb has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for OmniAb are expected to grow in the coming year, from ($0.35) to ($0.22) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of OmniAb is -12.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of OmniAb is -12.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

OmniAb has a P/B Ratio of 2.35. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.58% of the float of OmniAb has been sold short.

Short Interest Ratio / Days to Cover

OmniAb has a short interest ratio ("days to cover") of 1.85, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in OmniAb has recently decreased by 4.19%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

OmniAb does not currently pay a dividend.

Dividend Growth

OmniAb does not have a long track record of dividend growth.

News and Social Media

• Score: 3.7 / 5
• News Sentiment: 0.92

News Sentiment

OmniAb has a news sentiment score of 0.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.80 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for OmniAb this week, compared to 3 articles on an average week.

Search Interest

4 people have searched for OABI on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 1.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, OmniAb insiders have not sold or bought any company stock.

Percentage Held by Insiders

9.80% of the stock of OmniAb is held by insiders.

Percentage Held by Institutions

72.08% of the stock of OmniAb is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 9/16/2026
• Investor Day 2026: 10/06/2026
• Next Earnings (Estimated): 11/03/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Life Sciences Tools & Services
• Sub-Industry: Life Sciences Tools & Services
• Current Symbol: NASDAQ:OABI
• CIK: 1846253
• Web: www.omniab.com
• Phone: 510-250-7800
• Fax: N/A
• Employees: 89
• Year Founded: 2012

Price Target and Rating

• Average Price Target for OmniAb: $11.00
• High Price Target: $11.00
• Low Price Target: $11.00
• Potential Upside/Downside: +152.9%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.36)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$64.78 million
• Net Margins: -115.12%
• Pretax Margin: -118.86%
• Return on Equity: -16.59%
• Return on Assets: -14.82%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.80
• Quick Ratio: 4.80

Sales & Book Value

• Annual Sales: $18.67 million
• Price / Sales: 33.73
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.85 per share
• Price / Book: 2.35

Miscellaneous

• Outstanding Shares: 144,780,000
• Free Float: 130,594,000
• Market Cap: $629.79 million
• Optionable: Optionable
• Beta: 0.62